|
1 |
Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis
Henique, Carole. - Freiburg : Universität, 2019
|
|
|
|
2 |
Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis
Henique, Carole. - Frankfurt am Main : Universitätsbibliothek Johann Christian Senckenberg, 2017
|
|
|
3 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
Enthalten in BMC cancer Bd. 20, 25.4.2020, Nr. 1, date:12.2020: 1-11
|
|
|
|
4 |
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
Enthalten in Experimental hematology & oncology Bd. 12, 21.7.2023, Nr. 1, date:12.2023: 1-5
|
|
|
|
5 |
Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation
Enthalten in Clinical epigenetics Bd. 11, 12.10.2019, Nr. 1, date:12.2019: 1-14
|
|
|
|
6 |
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)
Enthalten in BMC cancer Bd. 23, 29.7.2023, Nr. 1, date:12.2023: 1-9
|
|
Administration
